Forgotten password

You now have access to Free InvestSMART Insights, we look forward to helping you on your financial journey.

You now have access to Free Eureka Report Insights. We look forward to helping you on your financial journey.

You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.

Looking for more…

Intelligent Investor Membership

15-day Free Trial

Indepth analysis of ASX listed shares

BUY, Hold and Sell Recommendations

Ideas Lab

Special Reports

No thanks

Looking for more…

Eureka Report Membership

15-day Free Trial

Alan Kohler’s Weekend Briefing

Interviews with CEO’s & top influencers

Money Cafe and Talking Finance

Super Advice and Q&A with Ask Alan

No thanks

Cochlear - $6.30: The company has won US regulatory approval for its advanced ear implant system which can be used on children as young as eighteen months. The implant has already been approved in most countries with its release in Europe last year boosting the company's sales in that region by 69%. The US approval is obviously a big win for the company and is expected to provide a significant boost to sales. We will be reviewing Cochlear in a forthcoming issue. Until then, the stock can be accumulated at current prices.

IMPORTANT: Intelligent Investor is published by InvestSMART Financial Services Pty Limited AFSL 226435 (Licensee). Information is general financial product advice. You should consider your own personal objectives, financial situation and needs before making any investment decision and review the Product Disclosure Statement. InvestSMART Funds Management Limited (RE) is the responsible entity of various managed investment schemes and is a related party of the Licensee. The RE may own, buy or sell the shares suggested in this article simultaneous with, or following the release of this article. Any such transaction could affect the price of the share. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.

IMPORTANT: This information is general financial product advice only and you should consider the relevant product disclosure statement (PDS) or seek professional advice before making any investment decision. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about a product. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.

* InvestSMART's capped Management Fee (capped at $451p.a.) does not include fees charged within any ETF held in this portfolio, estimated to be approximately 0.18% (indirect cost ratio). Brokerage costs are not included in this calculation. For more information about fees and costs, please see the Product Disclosure Statement and Investment Menu.

# InvestSMART Portfolio performance figures are after management and admin fees excl. brokerage and assuming dividends re-invested and no withdrawals. The peer comparison figures have been sourced from Morningstar data and is therefore limited to the funds and investment products included in their database. This may not include all funds available for retail investment in Australia. The peer calculation is inclusive of admin and management fees; excludes brokerage and no withdrawals have been made. InvestSMART cannot determine whether or not franking has been included, nor if dividends have been reinvested. Historical performance is not a reliable indicator of future performance.

^ Only funds and investment products included in the Morningstar Australia database are available for fee and performance comparison. This may not include all funds available for retail investment in Australia. Only funds with > three year returns were included in any fee comparison, and were compared to Morningstar's nominated benchmark. Fees are calculated by Morningstar as the average over 10 years. Whilst every care has been taken in producing these numbers, InvestSMART does not guarantee the accuracy of the figures produced in the table. Fee data may not include all costs being charged such as platform and adviser fees. For the effect of fees on your cumulative returns, please see our report How Fees Can Destroy Your Wealth.

^^ 557 Buy recommendations published by Intelligent Investor between 1 June 2001 and 30 June 2019 were independently verified by EY, as per the Recommendations Report; adjusted for franking, excludes admin and brokerage costs.